Potential for MM cure with CAR T-cell therapy in early treatment lines. Currently, CAR T-cell therapy is used in advanced disease settings. The benefit for patients is diminished by manufacturing failure/long vein-to-vein time periods, a high rate of (secondary) resistance that leads to relapse. Therefore, only a minority of patients remains in remission long term. In the future, CAR T-cell therapy ought to be implemented early in the disease course, which, we anticipate, will reduce the percentage of patients who are “lost” because of manufacturing failure or primary and secondary resistance and will lead to a fraction of patients who are long-term survivors after MM.